Page 57 - Read Online

Page 16 Biersack. Cancer Drug Resist 2019;2:1-17 I http://dx.doi.org/10.20517/cdr.2019.09

DNA methyltransferases indirectly. Oncotarget 2016;7:50229-38.
81. Xu J, Huang H, Peng R, Ding X, Jiang B, et al. MicroRNA-30a increases the chemosensitivity of U251 glioblastoma cells to
temozolomide by directly targeting beclin 1 and inhibiting autophagy. Exp Ther Med 2018;15:4798-804.
82. Wu H, Liu Q, Cai T, Chen YD, Liao F, et al. MiR-136 modulates glioma cell sensitivity to temozolomide by targeting astrocyte elevated
gene-1. Diagn Pathol 2014;9:173.
83. Wang L, Shi ZM, Jiang CF, Liu X, Chen Q, et al. MiR-143 acts as a tumor suppressor by targeting N-RAS and enhances temozolomide-
induced apoptosis in glioma. Oncotarget 2014;5:5416-27.
84. Chen R, Liu H, Cheng Q, Jiang B, Peng R, et al. MicroRNA-93 promotes the malignant phenotypes of human glioma cells and induces
their chemoresistance to temozolomide. Biol Open 2016;5:669-77.
85. Shi L, Zhang S, Feng K, Wu F, Wan Y, et al. MicroRNA-125b-2 confers human glioblastoma stem cell resistance to temozolomide
through the mitochondrial pathway of apoptosis. Int J Oncol 2012;40:119-29.
86. Chen L, Zhang J, Han L, Zhang A, Zhang C, et al. Downregulation of miR-221/222 sensitizes glioma cells to temozolomide by
regulating apoptosis independently of the p53 status. Oncol Rep 2012;27:854-60.
87. Zhou X, Wu W, Zeng A, Nie E, Jin X, et al. MicroRNA-141-3p promotes glioma cell growth and temozolomide resistance by directly
targeting p53. Oncotarget 2017;8:71080-94.
88. Peng Y, He X, Chen H, Duan H, Shao B, et al. Inhibition of microRNA-299-5p sensitizes glioblastoma cells to temozolomide via the
MAPK/ERK signaling pathway. Biosci Rep 2018;38:BSR20181051.
89. Tian T, Mingyi M, Qiu X, Qiu Y. MicroRNA-101 reverses temozolomide resistance by inhibition of GSK3b in glioblastoma. Oncotarget
2016;7:79584-95.
90. Chen PH, Cheng CH, Shih CM, Ho KH, Lin CW, et al. The inhibition of microRNA-128 on IGF-1-activating mTOR signaling involves
in temozolomide-induced glioma cell apoptotic death. PLoS One 2016;11:e0167096.
91. Chen H, Li X, Zheng H. MiR-130a can predict response to temozolomide in patients with glioblastoma multiforme, independently of
O6-methylguanine-DANN methyltransferase. J Transl Med 2015;13:69.
92. Kushwaha D, Ramakrishnan V, Ng K, Steed T, Nguyen T, et al. A genome-wide miRNA screen revealed miR-603 as a MGMT-
regulating miRNA in glioblastomas. Oncotarget 2014;5:4026-39.
93. Lee YY, Yarmishyn AA, Wang ML, Chen HY, Chiou SH, et al. MicroRNA-142-3p is involved in regulation of MGMT expression in
glioblastoma cells. Cancer Management Res 2018;10:775-85.
94. Kreth S, Limbeck E, Hinske LC, Schütz SV, Thon N, et al. In human glioblastomas transcript elongation by alternative polyadenylation
and miRNA targeting is a potent mechanism of MGMT silencing. Acta Neuropathol 2013;125:671-81.
95. Kouri FM, Hurley FA, Daniel WL, Day ES, Hua Y, et al. MiR-182 integrates apoptosis, growth, and differentiation programs in
glioblastoma. Genes Dev 2015;29:732-45.
96. Cheng ZX, Yin WB, Wang ZY. MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell
phenotypes by targeting tumor suppressor candidate 3 in glioblastoma. Int J Mol Med 2017;40:1307-14.
97. Gao YT, Chen XB, Liu HL. Up-regulation of miR-370-3p restores glioblastoma multiforme sensitivity to temozolomide by influencing
MGMT expression. Sci Rep 2016;6:32972.
98. Li S, Zeng A, Hu Q, Yan W, Liu Y, et al. MiR-423-5p contributes to a malignant phenotype and temozolomide chemoresistance in
glioblastomas. Neuro Oncol 2017;19:55-65.
99. Chen HY, Li WB, Zhang CB, Zhang W, Zheng HY. MiR-629-3p level significantly predicts prognosis in glioblastoma patients with
temozolomide chemotherapy. Curr Signal Transd Ther 2014;9:9-14.
100. Li XB, Wang J, Xu AD, Huang JM, Meng LQ, et al. The microRNA-1268 rs28599926 polymorphism modified diffusely infiltrating
astrocytoma risk and prognosis. Int J Clin Exp Med 2016;9:21615-24.
101. Chen H, Liu L, Li X, Shi Y, Liu N. MicroRNA-1294 inhibits the proliferation and enhances the chemosensitivity of temozolomide via
the direct targeting of TPX2. Am J Cancer Res 2018;8:291-301.
102. Ahir BK, Ozer H, Engelhard HH, Lakka SS. MicroRNAs in glioblastoma pathogenesis and therapy: a comprehensive review. Crit Rev
Oncol Hematol 2017;120:22-33.
103. Quintavalle C, Mangani D, Roscigno G, Romano G, Diaz-Lagares A, et al. MiR-221/222 target the DNA methyltransferase MGMT in
glioma cells. PLoS One 2013;8:e74466.
104. Bassiouny AR, Zaky A. Synergistic effect of curcumin on temozolomide inhibition of cancer stem cell-like properties and reduced
chemoresistance of glioblastoma C6. J Stem Cell Res Ther 2012;2:5.
105. Schepartz SA. Early history and development of the nitrosoureas. Cancer Treat Rep 1976;60:647-9.
106. Weiss RB, Issell BF. The nitrosoureas: carmustine (BCNU) and lomustine (CCNU). Cancer Treat Rev 1982;9:313-30.
107. Reithmeier T, Graf E, Piroth T, Trippel M, Pinsker MO, et al. BCNU for recurrent glioblastoma multiforme: efficacy, toxicity and
prognostic factors. BMC Cancer 2010;10:30.
108. Kohn KW. Interstrand coss-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-chloroethyl)-1-nitrosoureas. Cancer
Res 1977;37:1450-4.
109. Panasci LC, Green D, Nagourney R, Fox P, Schein PS. A structure-activity analysis of chemical and biological parameters of
chloroethylnitrosoureas in mice. Cancer Res 1977;37:2615-8.
110. Winkler JA, Hendricks WP, Johnson D, Xia J, Scheck AC. Global microRNA expression analysis in human malignant glioma cells
reveals novel miRNA-mediated therapy-resistance mechanisms. Proc Amer Assoc Cancer Res 2005;46:Abstract No 5942.
111. Wang GB, Liu JH, Hu J, Xue K. MiR-21 enhanced glioma cells resistance to carmustine via decreasing Spry2 expression. Eur Rev Med